Variation in TCF7L2 Influences Therapeutic Response to Sulfonylureas | Zendy

Ewan R. Pearson | Zendy; Louise A. Donnelly | Zendy; Charlotte H. Kimber | Zendy; Adrian L. Whitley | Zendy; Alex S. F. Doney | Zendy; Mark I. McCarthy | Zendy; Andrew T. Hattersley | Zendy; Andrew D. Morris | Zendy; Nicholette D. Palmer | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Variation in TCF7L2 Influences Therapeutic Response to Sulfonylureas

Author(s) -

Ewan R. Pearson,

Louise A. Donnelly,

Charlotte H. Kimber,

Adrian L. Whitley,

Alex S. F. Doney,

Mark I. McCarthy,

Andrew T. Hattersley,

Andrew D. Morris,

Nicholette D. Palmer

Publication year - 2007

Publication title -

diabetes

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.219

H-Index - 330

eISSN - 1939-327X

pISSN - 0012-1797

DOI - 10.2337/db07-0440

Subject(s) - tcf7l2 , metformin , medicine , sulfonylurea , type 2 diabetes , odds ratio , diabetes mellitus , endocrinology , genotype , biology , single nucleotide polymorphism , genetics , gene

There is considerable interindividual variation in sulfonylurea response in type 2 diabetes. Transcription factor 7-like 2 (TCF7L2) variants have been identified to be strongly associated with type 2 diabetes risk, probably due to decreased beta-cell function. We hypothesized that variation in TCF7L2 would influence response to sulfonylureas but not metformin. We studied the effect of TCF7L2 rs12255372 and rs7903146 genotypes on glycemic response.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research